Furthermore, since CD21 is only expressed in approximately two-third of B-cell lymphomas and only at low levels in half of those (Table I), our results may even be of clinical importance in selecting appropriate patients for anti-CD19 ADC therapy. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.